The future of liver transplantation
- PMID: 20304206
- DOI: 10.1016/j.transproceed.2010.02.003
The future of liver transplantation
Abstract
Liver transplantation has been a positive impact on both the survival and the quality of life of patients with advanced liver diseases. Progressive, spectacular improvements in the results of liver transplantation have been observed since the preliminary studies by Thomas Starzl in the United States and Roy Calne in Europe. This improvement is related to better knowledge of the natural history of liver diseases, allowing more adequate recipient selection, improvement of surgical techniques, progress in postoperative management, availability of potent antibacterial, antiviral, and antifungal drugs, as well as introduction of new immunosuppressive agents and protocols. These advances have occurred in the short interval of 45 years, suggesting future improvements in the liver transplantation field. The main investigative efforts in liver transplantation have been directed as follows: First attenuation of disproprortion between the numbers of available liver grafts versus waiting list recipients, by increasing the donor pool applying bioartificial support systems, or rendering grafts compatible by the use of stem cells. Second, improved knowledge about the biology of primary liver tumors establishes indications for and optimal moments of transplantation. Third, application of individualized immunosuppressive protocols, adapted to clinical status of the recipient, as well as the development of more selective, less toxic new immunosuppressive agents.
Copyright (c) 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Liver transplantation at the University of Wisconsin.Clin Transpl. 2002:207-13. Clin Transpl. 2002. PMID: 12971451
-
Update of the Adult and Pediatric Liver Transplant Program at the University of Michigan.Clin Transpl. 1996:203-16. Clin Transpl. 1996. PMID: 9286569
-
Current and future trends in liver transplantation in Europe.Gastroenterology. 2010 Mar;138(3):802-9.e1-4. doi: 10.1053/j.gastro.2010.01.030. Epub 2010 Jan 21. Gastroenterology. 2010. PMID: 20096694 Review. No abstract available.
-
Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.Transpl Immunol. 2004 Sep-Oct;13(2):139-46. doi: 10.1016/j.trim.2004.05.004. Transpl Immunol. 2004. PMID: 15380544
-
Changing perspectives on liver transplantation in 1988.Clin Transpl. 1988:5-27. Clin Transpl. 1988. PMID: 3154494 Review.
Cited by
-
''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation.World J Gastroenterol. 2014 Aug 28;20(32):11363-9. doi: 10.3748/wjg.v20.i32.11363. World J Gastroenterol. 2014. PMID: 25170223 Free PMC article.
-
Antitumor activities of Liver-targeting peptide modified Recombinant human Endostatin in BALB/c-nu mice with Hepatocellular carcinoma.Sci Rep. 2017 Oct 26;7(1):14074. doi: 10.1038/s41598-017-14320-0. Sci Rep. 2017. PMID: 29075040 Free PMC article.
-
Transplanted nonviable human hepatocytes produce appreciable serum albumin levels in mice.Stem Cell Res. 2010 Nov;5(3):267-70. doi: 10.1016/j.scr.2010.07.004. Epub 2010 Aug 5. Stem Cell Res. 2010. PMID: 20829142 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical